Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure
Fig 5
Prevalence of other RASs within NS5A in combination with signature L31/Y93 RAS.
Other RAS in combination with dual signature RAS (L31-RAS/Y93-RAS) were detected in 53% of patients. The prevalences of triple, quadruple, and quintuple RAS were 38%, 13%, and 2%, respectively.